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Mediators from both immune and non-immune cells play major
roles in glomerular disease processes. They are involved in
induction of the immune response, initiation of acute and chronic
inflammatory events and transition to repair or fibrosis. The latter
step requires regulatory mechanisms that help to limit the effects
of pro-inflammatory mediators by inhibiting their production,
stability or function. Of principal importance is the release of
glucocorticoids in response to inflammatory stress. The most
convincing example for the anti-inflammatory role of endogenous
glucocorticoids is given by experimental glomerulonephritis in
adrenalectomized rats [1]. Under these conditions, the glomerular
lesions induced by the administration of anti-glomerular base-
ment membrane (GBM) Ig are amplified, including the recruit-
ment of neutrophils and macrophages, and the induction of
proteinuria. In addition to glucocorticoids that exert endocrine
functions, local mediators with autocrine/paracrine functions con-
tribute to blunt the inflammatory response. They include anti-
inflammatory lipids and cytokines, soluble receptors and specific
antagonists. While previous attempts to reduce the pathological
consequences of an inflammatory response in the glomerulus have
focused on blocking the production of pro-inflammatory media-
tors, new therapeutic approaches are directed at amplifying the
network of these anti-inflammatory mediators.
The purpose of this work is to review our current knowledge of
endogenous anti-inflammatory substances and discuss their po-
tential role in regulating pro-inflammatory mediators in vivo, their
significance in glomerular diseases, and their potential use as
therapeutic agents.
ANTI-INFLAMMATORY LIPIDS
Polymorphonuclear neutrophils and monocytes/macrophages
accumulate in the glomerulus in early stages of many forms of
glomerulonephritis [2]. Upon activation, these cells release in
particular arachidonate 5-lipoxygenase derivatives, leukotriene-
(LT-)B4, LTC4 and LTD4. LTB4, a potent neutrophil chemotac-
tic agent, promotes neutrophil activation and degranulation and
amplifies neutrophil endothelial cell adhesion. LTD4, a vasoactive
agent, impairs glomerular filtration by causing mesangial cell
contraction and increases vascular permeability to macromole-
cules. Both polymorphonuclear leukocytes and monocytes/macro-
phages also release lipoxin(LX)A4, another arachidonate-derived
lipid mediator. This eicosanoid is formed via biosynthesis path-
ways that involve the dual lipoxygenation of arachidonic acid by
either 5-and 15-lipoxygenases or 5- and 12-lipoxygenases. Indeed,
during neutrophil-platelet interactions through P-selectin, LTA4
can be released from neutrophils and further converted to LXA4
by platelet 12-lipoxygenase [3–5]. Macrophages are a particularly
rich source of 15-lipoxygenase. Thus, dual lipoxygenation of
arachidonic acid at both the 5 and 15 positions yields LXA4
generation in these cells as well [6].
Both LXA4 and 15-(S)-HETE antagonize LTs and exert anti-
inflammatory effects in vitro. For instance, LXA4 inhibits LTD4-
induced adhesion of neutrophils to mesangial [7] and endothelial
cells [8]. The latter response requires the generation of endothe-
lial cell-derived cyclooxygenase products, mainly prostacyclin, and
the suppression of P-selectin mobilization from intracellular Wei-
bel-Palade bodies to the cell surface. In addition, LXA4 limits
neutrophil-endothelial cell adhesion triggered by LTB4 [8]. This
response, which is associated with a decrease in LTB4-induced
migration across endothelial cell monolayers, is mediated by the
down-regulation of LTB4-induced expression of b2 integrins. The
potential importance of LXA4 as an anti-inflammatory lipid is
further supported by the observation that LXA4 may also inhibit
neutrophil recruitment in vivo in experimental immune complex
glomerulonephritis [3]. In this context of glomerular inflamma-
tion, LXA4 may also be protective by improving renal blood flow
and glomerular filtration [6]. Indeed, LXA4 elicits vasorelaxant
responses in pre-glomerular arteriole vessels, thereby increasing
renal blood flow, transcapillary hydraulic pressure and glomerular
filtration. In addition, LXA4 antagonizes the intrarenal vasocon-
strictive actions of LTD4 [9]. Since 15-(S)-HETE can be oxygen-
ated to generate LX, it is likely that 15-(S)-HETE and LXA4
share anti-inflammatory activities. In fact, following its release,
15-(S)-HETE is rapidly esterified in phosphatidylinositol in neu-
trophils. Thereafter these cells show an impaired ability to
generate LTB4, and an enhanced ability to generate LX [10].
Thus, the anti-inflammatory activities of 15-(S)-HETE are ex-
plained by both the increase in LXA4 and the decrease in LTB4
[11].
LXA4 is generated in the kidney within minutes after induction
of both the Con-A/ferritin model of immune complex-mediated
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glomerulonephritis [3] and the anti-GBM nephritis [4]. By con-
trast, the formation of 15-(S)-hydroxyeicosatetraenoic acid [15-
(S)-HETE] increases slowly within hours after induction of the
anti-GBM nephritis [6].
The findings that LXA4 and 15-(S)-HETE exhibit anti-inflam-
matory activities have led to attempts to reduce the severity of
glomerulonephritis by increasing the availability of these eico-
sanoids. To this aim, Yura et al [12] have introduced hemagglu-
tinating virus of Japan (HVJ) liposomes containing human recom-
binant 15-lipoxygenase cDNA into rat kidney via the renal artery.
Glomerular cells continue to express transferred genes for at least
five days post-injection. Such a gene tranfer significantly reduces
nephrotoxic serum-induced glomerular lesions as assessed by
measuring the reduction of glomerular filtration and protein
excretion. This confirms the relevance of the in vitro data to the in
vivo inflammatory response, at the heterologous phase of the
disease.
By contrast with neutrophils, monocytes/macrophages are acti-
vated by LXs. For instance, LXA4 has been shown to be a potent
stimulant for migration and adherence of human monocytes [13].
Thus, overexpression of 15-lipoxygenase would be expected to
amplify the autologous phase of the disease, which depends on the
presence of macrophages. Further experimentation will be re-
quired to identify such potential adverse effects of 15-lipoxygen-
ase gene transfer.
ANTI-INFLAMMATORY INTERLEUKINS
Interleukin-4 and interleukin-13
The ability to resolve a glomerular inflammatory state through
15-lipoxygenase expression and activity depends on the balance
between the activities of pro-inflammatory cytokines such as
interferon-g (IFN-g) and anti-inflammatory interleukins (IL),
mainly IL-4 and IL-13. While IL-4 and IL-13, two lymphokines
produced by the helper T-lymphocyte subset 2 (Th-2) cells, induce
15-lipoxygenase mRNA and protein, IFN-g, a lymphokine pro-
duced by Th-1 cells, inhibits this induction [14, 15].
In addition to the expression of 15-lipoxygenase, IL-4 and IL-13
have been shown to trigger a great diversity of anti-inflammatory
responses. In particular, IL-4 abolishes IL-1-induced survival of
neutrophils [16]. The mechanism underlying this phenomenon has
been investigated: IL-4 as IL-13 [17] induces the expression and
the release of the IL-1 type II decoy receptor that acts as a
molecular trap for IL-1, inhibiting the effect of IL-1 on neutrophil
survival. Similarly, IL-4 and IL-13 up-regulate IL-1 type II decoy
receptor transcript and protein in monocytes and macrophages
[18]. Other anti-inflammatory properties of IL-4 and IL-13 in
monocytes and macrophages include a decrease in the cytotoxic
activity of these cells as well as in the release of IL-1, IL-8,
macrophage inflammatory protein 1-a, granulocyte-macrophage
colony-stimulating factor (GM-CSF), granulocyte colony-stimu-
lating factor (G-CSF), IFN-a and tumor necrosis factor-a
(TNF-a) [19]. In addition, they promote an increase in the
production of IL-1 receptor antagonist (IL-1 ra) by these cells.
Finally, IL-4 has been shown to have important regulatory prop-
erties on B cells and T cells. In particular, IL-4 enhances the
expression of Ia molecules on resting B cells and induces IgG1
and IgE antibody production. This cytokine plays a predominant
role in vitro in the differentiation of CD41 T cells into the Th-2
cells that are essential in some humoral responses.
During rat nephrotoxic serum nephritis, the glomerular expres-
sion of IL-4 mRNA increases gradually over the initial 16 hours so
that the peak expression precedes that of 15-lipoxygenase by four
to six hours [20, 21]. These data provide support for the notion
that IL-4 is responsible for 15-lipoxygenase mRNA expression.
Similar expression of IL-13 mRNA has been reported in rat
nephrotoxic nephritis [22]. By contrast, glomerular infiltrate of T
cells is not associated with IL-4 mRNA expression in the course of
Heymann nephritis, a rat model of human idiopathic membranous
nephritis [23].
In view of the monocyte/macrophage anti-inflammatory prop-
erties and Th-2 promoting activity ascribed to IL-4/IL-13, it has
been speculated that IL-4/IL-13 may be a therapeutic agent for
the treatment of experimental glomerulonephritis. While the
efficacy of IL-13 administration for the treatment of experimental
rheumatic diseases has been demonstrated [24], its importance for
the treatment of kidney diseases is still unknown. By contrast, the
therapeutic efficacy of IL-4 administration has been shown in
various models of glomerulonephritis. In particular, Tam et al [25]
have shown that administration of IL-4 reduces albuminuria and
glomerular capillary thrombi by 60 to 80% at the accelerated/
autologous phase of rat nephrotoxic serum nephritis. This protec-
tive effect is associated with a reduced response of infiltrating
macrophages to IL-1 via the local expression of the IL-1 type II
decoy receptor. A similar approach to attenuating glomerular
injury has been chosen by Tipping et al [26] in a model of
crescentic glomerulonephritis induced by the administration of
anti-GBM Ig to sensitized mice. The immunopathological fea-
tures of delayed type hypersensitivity (DTH), that have been
demonstrated in this model, are mediated by the Th1 subset of T
cells. The daily i.p. administration of recombinant mouse IL-4 to
Th-1 prone mice (C57 BL/6) starting prior to induction of the
disease abolishes crescent formation and attenuates both glomer-
ular fibrin deposition and local infiltration by macrophages and T
cells. This change in histological appearance is associated with a
decrease in proteinuria without improvement in glomerular filtra-
tion, and with a decline in serum titers of IgG2a and IgG3 globulin
isotypes. Thus, treatment with IL-4 yields selective suppression of
the Th-1 response and hence limits the development of crescentic
glomerulonephritis. In this case, the protective effect is not
associated with a reduced response of macrophages since the
accumulation of these cells is blunted. Interestingly, if adminis-
tered to mice after renal injury is established, IL-4 alone does not
attenuate crescent formation but still decreases both macrophage
and T cell infiltration [27]. In addition, IL-4 enhances the im-
provement provided by the administration of IL-10 in this model.
This concept that IL-4 is a potential agent for the treatment of
inflammatory diseases because of its ability to blunt Th-1 response
has been further demonstrated in lupus-like autoimmune syn-
drome [28]. Santiago et al have shown that the constitutive
expression of an IL-4 transgene by B cells prevents the develop-
ment and progression of lupus-like glomerulonephritis [28]. The
protective effect is associated with a decrease in IgG3 and IgG2a
subclasses of autoantibodies, which have been shown to be
especially nephritogenic. This is most likely due to the inhibitory
effect of IL-4 on the development of Th-1 response that is
involved in autoantibody production in this model.
Although IL-4 administration should be a promising therapeu-
tic approach for renal diseases characterized by inflammatory
processes and/or DTH responses, little is known about the
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side-effects of IL-4 administration. For example, IL-4 causes a
small increase in the expression of endothelial vascular cell
adhesion molecule-1 (VCAM-1) and markedly augments
VCAM-1 expression induced by TNF-a or IL-1 [29]. These
changes favor the binding of eosinophils and T cells to endothelial
cells. In addition, IL-4 stimulates the synthesis of the extracellular
matrix proteins, types I and III collagens and fibronectin by
fibroblasts [30], and type III collagen by mesangial cells [31].
Therefore, IL-4 could be responsible for the recruitment of T cells
at sites of inflammation and for the local development of fibrotic
lesions. Future studies should clarify these issues.
Neuropoietic cytokines
Another recently recognized and unusual family of cytokines,
neuropoietic cytokines, is also likely to control renal inflammatory
reaction. Leukemia inhibitory factor (LIF), IL-6 and IL-11 share
only limited sequence homology but exert very similar effects on
a variety of tissues [32]. Besides endothelial cells, T lymphocytes
and macrophages, mesangial cells are a potential source of LIF
since cultured mesangial cells of human and rat origin express LIF
mRNA upon exposure to lipopolysaccharide (LPS) and to either
pro-inflammatory cytokines [IL-1b, TNF-a, platelet-derived
growth factor (PDGF)] or anti-inflammatory cytokines (TGF-b)
[33, 34].
Glomerular expression of LIF mRNA occurs within three hours
after induction of the anti-GBM nephritis and persists through 24
hours [33]. Locally, LIF has the potential to decrease the intensity
of acute inflammation. Indeed, intraperitoneal infusion of LIF to
rats with anti-GBM nephritis using microosmotic pumps limits
proteinuria at the heterologous phase of the disease [33]. This
response is associated with a decrease in glomerular macrophage
infiltration and in MCP-1, IL-1 and TNF-a mRNA expression.
In contrast to LIF, IL-6 has complex effects in inflammatory
processes within the glomerulus. Renal overexpression of IL-6 has
been described in human glomerulonephritis characterized by
mesangioproliferative reaction such as IgA nephropathy and
some types of lupus nephritis [35]. In addition, a positive corre-
lation between the urinary IL-6 and the pathological score is
observed in IgA nephropathy and lupus nephritis [35], and urinary
IL-6/epidermal growth factor (EGF) ratio is a prognostic marker
for the progression of the renal damage in IgA nephropathy [36,
37]. These findings suggest a role for IL-6 in mediating mesangial
cell proliferation. They are also in agreement with experimental
data. In vivo, IL-6 transgenic mice develop a mesangioprolifera-
tive glomerulonephritis, and in vitro cultured mesangial cells,
which release IL-6 upon exposure to apoptotic monocytes [38],
immune complexes [39] and polymeric IgA [40], proliferate in
response to IL-6 challenge [37]. However, in vivo, IL-6 knockout
mice develop Habu snake venom-induced mesangioproliferative
glomerulonephritis, as control mice [41] and intraperitoneal infu-
sion of IL-6 to rats given anti-Thy 1.1 antibody does not modify
mesangioproliferative lesions [41]. In addition, depending on the
experimental design in vitro, the role of IL-6 on mesangial cell
proliferation can become undetectable [34] or even inhibitory
[42]. Thus, IL-6 is conceivably not an important mediator of
mesangial cell proliferation and extracellular matrix overproduc-
tion in vivo. Alternatively, this cytokine might affect inflammatory
processes within the glomerulus by blunting both the synthesis and
the bioactivity of pro-inflammatory cytokines. Indeed, IL-6 in-
duces the synthesis by hepatocytes of all major acute phase
proteins, including a2-macroglobulin [43]. In turn, a2-macroglob-
ulin that has been modified by proteinases such as plasmin, binds
pro-inflammatory cytokines, IL-1b and TNF-a. The a2-macro-
globulin-cytokine complexes are then cleared from the inflamma-
tory environment via the circulation or locally via macrophages
that express a2-macroglobulin receptors, so that the availability of
these cytokines is altered. In addition, IL-6 belongs to the
category of anti-inflammatory cytokines that both suppress IL-1
and TNF synthesis and induce the production or release of IL-1
and TNF antagonists, that is, IL-1 ra and soluble TNF receptor
p55, respectively [44].
All these activities suggest a therapeutic potential for IL-6 in
the management of cytokine-mediated glomerulonephritis. First,
Karkar et al [45] have investigated the influence of IL-6 on injury
in nephrotoxic serum nephritis in rats. These authors have
demonstrated that pretreatment of the rats with IL-6 blunts the
IL-1 and TNF dependent effects of LPS in exacerbating injury in
the heterologous phase of this disease. In particular, albumin
excretion, capillary thrombi formation and neutrophil infiltration
are limited. This protective effect is explained by a decrease in
glomerular expression of IL-1b and TNF rather than by an
increase in a2-macroglobulin synthesis. Anti-inflammatory prop-
erties of IL-6 are observed in the autologous phase [45] and
autologous/accelerated phase [46] of the disease as well. By
contrast, IL-6 administration has no effect on the development of
experimental mesangioproliferative glomerulonephritis [41], ex-
perimental IgA nephropathy [47] and glomerulonephritis in au-
toimmune MRL-lpr mice [48]. Moreover, IL-6 accelerates the
development of the genetically determined glomerulonephritis of
(NZB x NZW) F1 mice through effects mediated by modulation
of the immune system [49]. Collectively these findings suggest that
IL-6 has only a weak potential as a therapeutic agent in the
inflammatory disorders of the glomerulus.
The efficacy of IL-11, another neuropoietic cytokine, in this
context requires further experimentation. Indeed, by interacting
with macrophages, IL-11 limits the production of IL-1b, TNF-a
and nitric oxide, and its administration ameliorates a number of
animal models of acute and chronic inflammation, including
chronic inflammatory bowel disease in HLA-B27 rats [50].
Interleukin-10
Other potential therapies include the use of well characterized
deactivators of inflammatory macrophages such as IL-10. This
cytokine is produced by a variety of cells including the Th2 subset
of T cells, cytotoxic T cells, mast cells, B cells, activated macro-
phages [51] and, to a lesser extent, mesangial cells [52]. In vitro,
IL-10 synthesis occurs in response to monocyte/macrophage acti-
vation by immune complexes, LPS, pro-inflammatory cytokines
(mainly TNF-a) [53] and various mediators or hormones that are
known to elevate intracellular cyclic AMP, such as prostaglandin
E2 (PGE2) [54] and catecholamines [55]. Interestingly, transform-
ing growth factor-b (TGF-b) is also effective at inducing IL-10
synthesis through still unknown mechanisms [52, 56].
Interleukin-10 interacts in particular with macrophages, poly-
morphonuclear leukocytes and mesangial cells. Monocyte/macro-
phage exposure to IL-10 inhibits the production of IL-1a, IL-1b,
IL-6, IL-8, TNF-a, GM-CSF, G-CSF [57], reactive oxygen species,
reactive nitrogen intermediates, tissue factor [58] and PGE2 [59].
Similar suppressive effects of IL-10 have been described on
polymorphonuclear leukocytes [60] and mesangial cells [52].
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Thus, IL-10 may also have an important regulatory role in limiting
the duration and extent of acute inflammatory processes. How-
ever, this role is potentially limited by pro-inflammatory actions of
IL-10. First, IL-10 induces the expression of E-selectin on endo-
thelial cells, a process crucial to the accumulation of neutrophils
at the site of inflammation [61]. Second, while decreasing the
antigen-presenting activity of monocytes/macrophages by down-
regulating the expression of MHC class II, B7.1 and intercellular
adhesion molecule-1 (ICAM-1) [62], IL-10 serves as a cofactor in
promoting the growth of T cells, B cells and mast cells. It also
enhances the differentiation of B cells, up-regulates the cytolytic
activity of NK cells and serves as a chemoattractant for CD81 T
cells [51]. Through the latter mechanisms, cellular IL-10 but not
its EBV homologue, viral IL-10, elicits the rejection of established
tumors [63, 64]. Finally, IL-10 serves as a mediator of mesangial
cell proliferation both in vitro and in vivo [65].
In vivo, the expression of IL-10 within the glomerulus increases
two hours following the induction of experimental nephrotoxic
serum nephritis [17]. The ability of IL-10 to blunt the inflamma-
tory response led us to determine whether increasing its availabil-
ity could reduce the severity of glomerular lesions in that model.
First, we assessed the therapeutic role of IL-10 in the heterolo-
gous phase of nephrotoxic serum nephritis [66]. To this aim,
microosmotic pumps loaded with recombinant human IL-10 or
saline vehicle were implanted into the peritoneum of rats, 24
hours before inducing the nephritis. This lead to a 75% decrease
in 24-hour urinary protein excretion in rats infused with IL-10 as
compared with rats given saline alone. These changes, which
depend on the IL-10 dose between 25 and 225 ng/kg/day, are
apparently not associated with a reduction in the binding of the
anti-GBM antibody. To determine the therapeutic role of IL-10 in
the autologous phase of the disease, we used the technique
described by Kitamura et al [67] in which glomerular mesangial
cells serve as a vector for gene delivery. Human IL-10 transfec-
tants were transferred into glomeruli of the left kidney via renal
artery injection immediately after induction of the nephritis. In
situ expression of human IL-10 continued for up to 21 days after
cell transfer. At that time, urinary protein excretion decreased
slightly in the left ureter as compared to the right one (223%).
The expression of transfected gene in less than 30% of the
glomeruli may provide a mechanism for this weak anti-inflamma-
tory effect. To overcome this obstacle, we used an established
gene transfer technique in which DNA-containing HVJ-liposomes
were injected into skeletal muscles [68]. By this way, IL-10 gene
expression in skeletal muscles lead to IL-10 secretion and delivery
to all the glomeruli. As a consequence, urinary protein excretion
at the autologous phase of the disease is reduced by 55%. In
contrast, Chadban et al [69] reported that IL-10 is not an effective
treatment for rat crescentic anti-GBM glomerulonephritis. In that
model, immunized rats received daily s.c. injections of recombi-
nant mouse IL-10 from the time of anti-GBM rabbit serum
administration. Such a treatment limited renal up-regulation of
IL-1b, but was not sufficient to prevent IL-1b-dependent mecha-
nisms of glomerular injury. In addition, it facilitated renal damage
by exaggerating the humoral immune response, as shown by an
increase in serum levels of anti-rabbit IgG. While ineffective in
the rat model of crescentic glomerulonephritis, IL-10 administra-
tion attenuated crescent formation and glomerular injury in
mouse models [26, 27]. In a first model, mice received daily i.p.
injections of recombinant mouse IL-10 from the time of sensiti-
zation up to 10 days after administration of sheep anti-GBM
globulin [26]. The treatment prevented crescent formation, glo-
merular fibrin deposition, glomerular accumulation of T cells and
macrophages. This protection of glomerular structure was associ-
ated with a decrease in proteinuria and an attenuation of the
decline in creatinine clearance. Interestingly, the treatment did
not increase the serum levels of anti-sheep globulin, but affected
the relative concentration of immunoglobulin isotypes. There was
a marked decline in the IgG2a and IgG3 immunoglobulin isotypes
associated with Th-1 responses and a relative sparing of IgG1, a
Th-2-associated immunoglobulin isotype. In a second model, mice
with crescentic glomerulonephritis received the IL-10 treatment
after glomerular injury was established [27]. Administration of
IL-10 attenuated the development of glomerular crescent forma-
tion and protected renal function in that model as well. Thus, in
mice, IL-10 is effective in both prevention and treatment of
glomerulonephritis models that are associated with a Th-1 im-
mune response to an antigen planted within the glomerulus.
Conversely, continuous administration of IL-10 accelerates the
onset of disease in glomerulonephritis models that are associated
with a Th-2 immune response, such as lupus nephritis in NZB/W
F1 mice [70].
SPECIFIC ANTAGONISTS AND SOLUBLE RECEPTORS
Interleukin-1 receptor antagonist
The balance between IL-1 and IL-1 ra is an important regulat-
ing mechanism needed to maintain limited inflammatory pro-
cesses within the glomerulus. Monocytes can synthesize both
IL-1a/IL-1b and IL-1 ra simultaneously, but through separate
mechanisms of regulation. For instance, LPS stimulates produc-
tion of both molecules in equal amounts while IgG induces only
IL-1 ra protein. IL-1 ra binds specifically to both known types of
IL-1 receptors and competitively inhibits the binding of both
IL-1a and IL-1b [71]. In contrast with IL-1, this molecule fails to
induce interiorization of ligand-receptor complexes and to stim-
ulate intracellular responses. In fact, 10- to 500-fold excess
amounts of IL-1 ra over IL-1 are necessary to reduce by 50% cell
responses to IL-1 in vitro.
In vivo, glomerular cells express IL-1 ra mRNA at the autolo-
gous/accelerated phase of nephrotoxic serum nephritis in the rat
[72]. This expression peaks six hours after induction of the disease
and persists up to 96 hours so that excess amounts of IL-1 ra over
IL-1 reach 10-fold at six hours and 20-fold at later time points.
Thus, endogenous IL-1 ra amounts are probably insufficient to
inhibit the action of IL-1 in this model.
One approach to tip the balance toward an anti-inflammatory
response is to up-regulate IL-1 ra expression either by adminis-
tering recombinant IL-1 ra protein or by using gene transfer
techniques. Intravenous injection of IL-1 ra before the induction
of nephrotoxic serum nephritis in rats given LPS limits albumin
excretion, glomerular capillary thrombi formation and glomerular
neutrophil infiltration at the heterologous phase of the disease
[73]. In addition, constant s.c. infusion of IL-1 ra from the
induction of nephrotoxic serum nephritis in sensitized rats pre-
vents the development of the autologous/accelerated phase of the
disease [74, 75]. In particular, ICAM-1 expression and leukocyte
infiltration are partially reduced within the glomerulus while they
are dramatically blunted in the interstitium. Of greater impor-
tance, constant infusion of IL-1 ra starting from the day 7 is
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effective in reducing the severity of the progressive phase of
established crescentic glomerulonephritis [76]. This treatment
suppresses glomerular cell proliferation and limits both crescent
formation and fibrosis development. Because locally expressed
IL-1 ra has been shown to be about four orders of magnitude
more therapeutically efficient than systemically administered re-
combinant IL-1 ra protein [77], further studies should examine the
efficiency of IL-1 ra gene transfer approach. So far only the
feasibility of this technique has been assessed. Using the glomer-
ular mesangial cell as a vector for IL-1 ra gene delivery, Yokoo
and Kitamura [78] have demonstrated that glomeruli transferred
with these cells are insensitive to IL-1. Thus, further experimen-
tation will be required to identify the importance of this response
in the control of inflammatory processes within the glomerulus.
Soluble cytokine receptors
Soluble cytokine receptors provide another natural source of
highly selective inhibitors of pro-inflammatory cytokines [79]. To
date, information in this regard comes from studies of soluble
IL-1 and TNF-a receptors. Two receptors for IL-1, termed type I
and type II (RI and RII, respectively), are coexpressed in different
cell types. IL-1 signaling activity seems to be mediated exclusively
via RI, whereas IL-1 RII has no signaling property and acts as a
“decoy” for IL-1. Thus, IL-1 RII inhibits IL-1 activity by prevent-
ing IL-1 from binding to the signaling RI [80]. In addition to
membrane expression of IL-1 RI and IL-1 RII, activated inflam-
matory cells secrete a soluble form of these receptors that retains
the ability to bind IL-1 [81]. By this way, soluble IL-1 receptors
can compete with membrane receptors for binding of IL-1, and
are generally regarded as inhibitors. The efficacy of these mole-
cules as potential therapeutic agents has been assessed in exper-
imental glomerulonephritis. Intravenous injection of soluble IL-1
RI before the induction of nephrotoxic serum nephritis in rats
given LPS limits glomerular injury similarly to IL-1 ra adminis-
tration [73]. This response would be potentially improved by using
soluble IL-1 RII instead of soluble IL-1 RI. Indeed, soluble IL-1
RII displays a lower affinity for IL-1 ra than soluble IL-1 RI, so
that soluble IL-1 RII does not blunt IL-1 ra efficacy [82].
Bioactivity of TNF-a may also be regulated, at least in part, by
naturally occurring soluble TNF-binding proteins released after
proteolytic cleavage of cell surface TNF-receptors of 55 to 60 or
75 to 80 kDa (TNF-R1 and TNF-R2, respectively). Indeed, stimuli
that induce the release of TNF-a also trigger the shedding of TNF
receptors through the activation of serine proteases such as
elastase and/or matrix metalloproteinases [83]. In turn, shed TNF
receptors may function either as antagonists of TNF biologic
activity by competitively inhibiting TNF interaction with cell
surface receptors [84], or as TNF agonists, by stabilizing the
trimeric structure of TNF [85]. In vivo, recombinant analogs of the
soluble TNF receptors have shown potent TNF-neutralizing ac-
tivity. In rats pretreated with soluble recombinant human TNF-
R1, the development of acute nephrotoxic serum nephritis is
blunted [86]. In particular, glomerular expression of leukocyte
adhesion molecules (ICAM-1, ELAM-1, VCAM-1), accumulation
of neutrophils and proteinuria are considerably reduced. It may
be possible to improve these results by using chimeric fusion
proteins combining extracellular TNF receptors with Ig heavy
chain sequences instead of soluble TNF receptors. Indeed, as
compared with monomeric recombinant receptors, TNF recep-
tor-Fc fusion proteins have higher binding affinity for TNF-a and
increased serum half-life [87].
OTHER
An alternative approach for limiting inflammatory processes
within the glomerulus would implicate TGF-b, which shares
anti-inflammatory properties of IL-10 [88]. Of the TGF-b iso-
forms, TGF-b1 is the most highly expressed in glomerular dis-
eases. There is a marked increase in TGF-b1 expression and
bioactivity in the glomeruli immediately upon injury in the acute
mesangial proliferative glomerulonephritis induced in the rat by a
single injection of anti-thymocyte anti-serum [89] and in the
nephrotoxic serum nephritis induced in the rabbit [90], as well as
in several non-inflammatory glomerular diseases. By contrast,
complement-mediated injury of glomerular epithelial cells in
experimental membranous nephropathy is associated with the
up-regulation of TGF-b2 and TGF-b3 without any change in
TGF-b1 expression [91]. The role of TGF-b in the development
of glomerulosclerosis has been established experimentally. In
vitro, exposure of cells to TGF-b stimulates synthesis of collagen,
fibronectin and proteoglycans and decreases their catabolism,
causing accumulation of extracellular matrix. In vivo introduction
of the TGF-b gene into the kidney induces glomerulosclerosis
[92]. Conversely, inhibition of TGF-b1 expression by antisense
oligonucleotides [93] or suppression of TGF-b1 bioactivity using
TGF-b1 specific antiserum [94] or decorin, a TGF-b1 binding
proteoglycan, [68, 95] prevents glomerular extracellular matrix
expansion in experimental mesangial proliferative glomerulone-
phritis. If TGF-b1 is harmful in promoting matrix production and,
hence, glomerulosclerosis, it may be of some benefit as well by
limiting both proliferative and inflammatory responses in the
glomerulus. Indeed, TGF-b inhibits mitogen-stimulated mesan-
gial cell growth by causing cell cycle arrest in late G1 phase [96]
and deactivates macrophages by impairing their adhesiveness [97]
and by inhibiting the release of reactive oxygen intermediates,
reactive nitrogen intermediates, IL-1a, IL-1b and TNF-a [98]. In
addition, TGF-b stimulates arginase activity in macrophages,
leading to the release of more polyamines, mainly putrescine [99].
In turn, polyamines limit macrophage-dependent cytotoxicity and
accelerate the process of repair. Whether such anti-inflammatory
activities of TGF-b also operate in vivo has been nicely demon-
strated in gene-knockout experiments. TGF-b1 null mice exhibit
an excessive inflammatory response with massive infiltration of
lymphocytes and macrophages in many organs, mainly heart and
lungs [100]. Conversely, this indicates that TGF-b may be poten-
tially considered as a therapeutic agent in inflammatory disorders
of the glomerulus. Kitamura et al [101] examined the anti-
inflammatory potential of TGF-b1 in experimental mesangial
proliferative glomerulonephritis. Using the glomerular mesangial
cell as a vector for mutated TGF-b1 gene delivery, these authors
obtained a sustained expression of bioactive TGF-b in glomeruli.
This was associated with a decrease in glomerular cell prolifera-
tion possibly related to the decreased release of cytokines by
activated local macrophages.
CONCLUDING REMARKS AND PERSPECTIVES
Despite the success of natural inhibitors of pro-inflammatory
mediators as anti-inflammatory agents in experimental models of
glomerulonephritis, various flaws pose a major impediment to the
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successful use of these agents in the treatment of human glomer-
ulonephritis. First, a considerable amount of experimental data
support the conclusion that natural anti-inflammatory mediators
prevent glomerular lesions if given before inducing the disease.
Much less is known, however, about the factors that limit the
progression of established glomerular lesions. Second, natural
anti-inflammatory mediators could have untoward side effects
(such as glomerulosclerosis), especially with systemic and long-
term therapy. An approach to resolve the latter difficulty would be
to deliver the therapeutic agent locally and transiently. One of the
first approaches to promote gene transfer specifically into the
glomerulus has been to engineer mesangial cells [102] or macro-
phages [103] ex vivo and to introduce these cells into the renal
circulation. Thereafter, the engineered cells remain against the
wall of glomerular capillaries or thread their way between mes-
angial cells. Thus, this delivery system is possibly site-specific for
the glomerulus. Nevertheless, it results in gene transfer into less
than 50% of kidney glomeruli. Another approach has been to
inject HVJ-liposomes into the renal circulation. Such liposomes
fuse rapidly with the plasma membrane of endothelial cells
through the interaction of HVJ glycoproteins with sialic acids.
They deliver DNA directly into the cytoplasm, avoiding its
degradation in endosomes/lysosomes [104]. Thereafter, the nu-
clear migration of DNA is facilitated by a non-histone chromo-
somal protein, high-mobility group I (HMG-I), coencapsulated
with DNA in liposomes. To express exogenous genes only in cells
within the glomerulus and for a controlled period of time, the
transgenes encapsulated into HVJ-liposomes would have to be
driven by cell type-specific promoters and inducible promoters,
respectively. These strategies are currently under investigation
[105, 106]. Third, optimal treatment of glomerulonephritis may
require a combination of anti-inflammatory mediators because of
the intertwined nature of the cytokine pathways. For instance,
IL-4 and IL-10 in combination are more efficient than IL-4 or
IL-10 in isolation to attenuate injury in crescentic glomerulone-
phritis [26, 27]. Future studies could also concern the association
of anti-inflammatory mediators with anti-inflammatory hormones
such as glucocorticoids. Finally, because anti-inflammatory medi-
ator administration or anti-inflammatory gene transfer have lim-
itations in terms of efficiency and untoward effects, a number of
other approaches to blocking pro-inflammatory mediators are
being investigated. In particular, these include strategies to mimic
the signaling mechanism specifically involved in cell response to
anti-inflammatory mediators. For example, the efficacy of various
anti-inflammatory mediators including IL-10 [107] depends on the
inhibition of nuclear factor-kB (NF-kB), a factor responsible for
the transcription of genes mediating inflammatory processes.
Thus, in vivo transfer of decoy oligodeoxynucleotides with a high
affinity for NF-kB would reproduce the efficacy of anti-inflamma-
tory mediators. Preliminary results indicate that administration of
decoy oligodeoxynucleotides targeting NF-kB effectively limits
the inflammatory processes in experimental mesangial prolifera-
tive glomerulonephritis as assessed by a decrease in mesangial cell
proliferation and TNF-a expression [108]. Like all new therapeu-
tic approaches, much remains to be learned about the optimal use
of this strategy and also about its limitations.
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APPENDIX
Abbreviations used in this article are: DTH, delayed type hypersensi-
tivity; EGF, epidermal growth factor; GBM, glomerular basement mem-
brane; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulo-
cyte-macrophage colony-stimulating factor; HMG-1, high-mobility group
I; HVJ, hemagglutinating virus of Japan; ICAM-1, intercellular adhesion
molecule-1; IF, interferon; IL, interleukin; IL-1 ra, interleukin-1 receptor
antagonist; LIF, leukemia inhibitory factor; LPS, lipopolysaccharide; LT,
leukotriene; LX, lipoxin; NF-kB, nuclear factor-kB PDGF, platelet-
derived growth factor; PGE2, prostaglandin E2; 15-(S)-HETE, 15-(S)-
hydroxyeicosatetraenoic acid; TGF-B, transforming growth factor-B;
TH-2, helper T-lymphycyte subset 2; TNF-a, tumor necrosis factor-alpha;
TNF-R1 and TNF-R2, tumor necrosis factor receptors; VCAM-1 vascular
cell adhesion molecule-1.
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